MERAIODE: A Redifferentiation Phase II Trial With Trametinib and Dabrafenib Followed by Radioactive Iodine Administration for Metastatic Radioactive Iodine Refractory Differentiated Thyroid Cancer Patients With a BRAFV600E Mutation (NCT 03244956)

Background: Two-thirds of patients with metastatic differentiated thyroid cancer (DTC) become refractory to radioactive iodine (RAIR). The inhibition of the MAP-kinase pathway that is activated in case of BRAFV600E mutation might increase RAI incorporation into metastatic foci and reverse the RAI re...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Endocr Soc
Glavni autori: Leboulleux, Sophie, Cao, Christine Do, Zerdoud, Slimane, Attard, Marie, Bournaud, Claire, Benisvy, Danielle, Taieb, David, Bardet, Stephane, Terroir-Cassou-Mounat, Marie, Betrian, Sarah, Lion, Georges, Schiazza, Aurelie, Sajous, Christophe, Garcia, Marie-Eve, Schlumberger, Martin Jean, Godbert, Yann, Borget, Isabelle
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2021
Teme:
Thyroid
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8089684/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvab048.1789
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items